Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

NEDD4-induced degradative ubiquitination of phosphatidylinositol 4-phosphate 5-kinase α and its implication in breast cancer cell proliferation.

Tran MH, Seo E, Min S, Nguyen QT, Choi J, Lee UJ, Hong SS, Kang H, Mansukhani A, Jou I, Lee SY.

J Cell Mol Med. 2018 Sep;22(9):4117-4129. doi: 10.1111/jcmm.13689. Epub 2018 May 30.

2.

Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma.

Maurizi G, Verma N, Gadi A, Mansukhani A, Basilico C.

Oncogene. 2018 Aug;37(33):4626-4632. doi: 10.1038/s41388-018-0292-2. Epub 2018 May 10.

3.

Myeloid Zinc Finger 1 and GA Binding Protein Co-Operate with Sox2 in Regulating the Expression of Yes-Associated Protein 1 in Cancer Cells.

Verma NK, Gadi A, Maurizi G, Roy UB, Mansukhani A, Basilico C.

Stem Cells. 2017 Dec;35(12):2340-2350. doi: 10.1002/stem.2705. Epub 2017 Sep 29.

4.

Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.

Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH.

Oncotarget. 2017 Mar 7;8(10):17406. doi: 10.18632/oncotarget.15921. No abstract available.

5.

Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.

Liao S, Ruiz Y, Gulzar H, Yelskaya Z, Ait Taouit L, Houssou M, Jaikaran T, Schvarts Y, Kozlitina K, Basu-Roy U, Mansukhani A, Mahajan SS.

PLoS One. 2017 Feb 23;12(2):e0171256. doi: 10.1371/journal.pone.0171256. eCollection 2017.

6.

Cruciate Paralysis in a 20- year -old Male with an Undisplaced Type III Odontoid Fracture.

A MS, V TS, B DS.

J Orthop Case Rep. 2016 Apr-Jun;6(2):40-42. doi: 10.13107/jocr.2250-0685.424.

7.

PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity.

Basu-Roy U, Han E, Rattanakorn K, Gadi A, Verma N, Maurizi G, Gunaratne PH, Coarfa C, Kennedy OD, Garabedian MJ, Basilico C, Mansukhani A.

Oncotarget. 2016 Sep 20;7(38):60954-60970. doi: 10.18632/oncotarget.11273.

8.

miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.

Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, Basu-Roy U, Mansukhani A, Chu A, Sipahimalani P, Bowlby R, Brooks D, Thiessen N, Coarfa C, Ma Y, Moore RA, Schein JE, Mungall AJ, Liu J, Pecot CV, Sood AK, Jones SJ, Marra MA, Gunaratne PH.

Oncotarget. 2016 May 3;7(18):25930-48. doi: 10.18632/oncotarget.8412. Erratum in: Oncotarget. 2017 Mar 7;8(10 ):17406.

9.

Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase Cγ.

Huang Z, Marsiglia WM, Basu Roy U, Rahimi N, Ilghari D, Wang H, Chen H, Gai W, Blais S, Neubert TA, Mansukhani A, Traaseth NJ, Li X, Mohammadi M.

Mol Cell. 2016 Jan 7;61(1):98-110. doi: 10.1016/j.molcel.2015.11.010. Epub 2015 Dec 10. Erratum in: Mol Cell. 2016 Jan 21;61(2):324.

10.

Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.

Basu-Roy U, Bayin NS, Rattanakorn K, Han E, Placantonakis DG, Mansukhani A, Basilico C.

Nat Commun. 2015 Apr 2;6:6411. doi: 10.1038/ncomms7411.

11.

Alternatively activated macrophages derived from monocytes and tissue macrophages are phenotypically and functionally distinct.

Gundra UM, Girgis NM, Ruckerl D, Jenkins S, Ward LN, Kurtz ZD, Wiens KE, Tang MS, Basu-Roy U, Mansukhani A, Allen JE, Loke P.

Blood. 2014 May 15;123(20):e110-22. doi: 10.1182/blood-2013-08-520619. Epub 2014 Apr 2.

12.

SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage.

Seo E, Basu-Roy U, Gunaratne PH, Coarfa C, Lim DS, Basilico C, Mansukhani A.

Cell Rep. 2013 Jun 27;3(6):2075-87. doi: 10.1016/j.celrep.2013.05.029. Epub 2013 Jun 20.

13.

Molecular studies on the roles of Runx2 and Twist1 in regulating FGF signaling.

Lu Y, Li Y, Cavender AC, Wang S, Mansukhani A, D'Souza RN.

Dev Dyn. 2012 Nov;241(11):1708-15. doi: 10.1002/dvdy.23858. Epub 2012 Sep 17.

14.

Perspectives on cancer stem cells in osteosarcoma.

Basu-Roy U, Basilico C, Mansukhani A.

Cancer Lett. 2013 Sep 10;338(1):158-67. doi: 10.1016/j.canlet.2012.05.028. Epub 2012 May 29. Review.

15.

Distinct functions of Sox2 control self-renewal and differentiation in the osteoblast lineage.

Seo E, Basu-Roy U, Zavadil J, Basilico C, Mansukhani A.

Mol Cell Biol. 2011 Nov;31(22):4593-608. doi: 10.1128/MCB.05798-11. Epub 2011 Sep 19.

16.

Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas.

Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, Mansukhani A, Basilico C.

Oncogene. 2012 May 3;31(18):2270-82. doi: 10.1038/onc.2011.405. Epub 2011 Sep 19.

17.

The transcription factor Sox2 is required for osteoblast self-renewal.

Basu-Roy U, Ambrosetti D, Favaro R, Nicolis SK, Mansukhani A, Basilico C.

Cell Death Differ. 2010 Aug;17(8):1345-53. doi: 10.1038/cdd.2010.57. Epub 2010 May 21.

18.

Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology.

Holmes G, Rothschild G, Roy UB, Deng CX, Mansukhani A, Basilico C.

Dev Biol. 2009 Apr 15;328(2):273-84. doi: 10.1016/j.ydbio.2009.01.026. Epub 2009 Jan 29.

19.

Endothelium-targeted overexpression of constitutively active FGF receptor induces cardioprotection in mice myocardial infarction.

Matsunaga S, Okigaki M, Takeda M, Matsui A, Honsho S, Katsume A, Kishita E, Che J, Kurihara T, Adachi Y, Mansukhani A, Kobara M, Matoba S, Tatsumi T, Matsubara H.

J Mol Cell Cardiol. 2009 May;46(5):663-73. Erratum in: J Mol Cell Cardiol. 2009 Sep;47(3):419. Matoba, Yoshiaki [corrected to Matoba, Satoaki]; Jishan, Che [corrected to Che, Jishan].

PMID:
19358330
20.

Fibroblast growth factor signaling uses multiple mechanisms to inhibit Wnt-induced transcription in osteoblasts.

Ambrosetti D, Holmes G, Mansukhani A, Basilico C.

Mol Cell Biol. 2008 Aug;28(15):4759-71. doi: 10.1128/MCB.01849-07. Epub 2008 May 27.

21.

Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor.

Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, Witte ON.

Cancer Cell. 2007 Dec;12(6):572-85.

22.

Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways.

Raucci A, Bellosta P, Grassi R, Basilico C, Mansukhani A.

J Cell Physiol. 2008 May;215(2):442-51.

PMID:
17960591
23.

The Mood Spectrum Self-Report: validation and adaptation into Spanish.

Berrocal C, Ruiz Moreno M, Merchán P, Mansukhani A, Rucci P, Cassano GB.

Depress Anxiety. 2006;23(4):220-35.

PMID:
16550540
24.

Mechanisms underlying differential responses to FGF signaling.

Dailey L, Ambrosetti D, Mansukhani A, Basilico C.

Cytokine Growth Factor Rev. 2005 Apr;16(2):233-47. Epub 2005 Mar 5. Review.

PMID:
15863038
25.

Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation.

Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L, Basilico C.

J Cell Biol. 2005 Mar 28;168(7):1065-76. Epub 2005 Mar 21.

26.

Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes.

Raucci A, Laplantine E, Mansukhani A, Basilico C.

J Biol Chem. 2004 Jan 16;279(3):1747-56. Epub 2003 Oct 30.

27.

p21(WAF1/CIP1) acts as a brake in osteoblast differentiation.

Bellosta P, Masramon L, Mansukhani A, Basilico C.

J Bone Miner Res. 2003 May;18(5):818-26.

28.

Role of fibroblast growth factor receptor signaling in prostate cancer cell survival.

Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M.

J Natl Cancer Inst. 2001 Dec 5;93(23):1783-90.

PMID:
11734594
29.

Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer.

Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M.

Cancer Res. 2000 Aug 1;60(15):4245-50.

31.

FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway.

Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C.

Genes Dev. 1999 Jun 1;13(11):1361-6.

32.

FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells.

Johnson MR, Valentine C, Basilico C, Mansukhani A.

Oncogene. 1998 May;16(20):2647-56.

33.

Mutation associated with Crouzon syndrome causes ligand-independent dimerization and activation of FGF receptor-2.

Mangasarian K, Li Y, Mansukhani A, Basilico C.

J Cell Physiol. 1997 Jul;172(1):117-25.

PMID:
9207932
34.

Activation of FGF receptors by mutations in the transmembrane domain.

Li Y, Mangasarian K, Mansukhani A, Basilico C.

Oncogene. 1997 Mar 27;14(12):1397-406.

35.

Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate.

Ittman M, Mansukhani A.

J Urol. 1997 Jan;157(1):351-6.

PMID:
8976296
36.

Retinal degeneration in transgenic mice with photoreceptor-specific expression of a dominant-negative fibroblast growth factor receptor.

Campochiaro PA, Chang M, Ohsato M, Vinores SA, Nie Z, Hjelmeland L, Mansukhani A, Basilico C, Zack DJ.

J Neurosci. 1996 Mar 1;16(5):1679-88.

38.
39.

Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding.

Roghani M, Mansukhani A, Dell'Era P, Bellosta P, Basilico C, Rifkin DB, Moscatelli D.

J Biol Chem. 1994 Feb 11;269(6):3976-84.

40.

Characterization of the murine BEK fibroblast growth factor (FGF) receptor: activation by three members of the FGF family and requirement for heparin.

Mansukhani A, Dell'Era P, Moscatelli D, Kornbluth S, Hanafusa H, Basilico C.

Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3305-9.

41.

A putative receptor tyrosine kinase with unique structural topology.

Rescigno J, Mansukhani A, Basilico C.

Oncogene. 1991 Oct;6(10):1909-13.

PMID:
1840679
42.

Response.

Kaner RJ, Baird A, Florklewicz RZ, Mansukhani A, Basilico C, Hajjar DP.

Science. 1991 Jul 12;253(5016):209-10. No abstract available.

PMID:
17779135
43.

Fibroblast growth factor receptor is a portal of cellular entry for herpes simplex virus type 1.

Kaner RJ, Baird A, Mansukhani A, Basilico C, Summers BD, Florkiewicz RZ, Hajjar DP.

Science. 1990 Jun 15;248(4961):1410-3.

PMID:
2162560
44.

A murine fibroblast growth factor (FGF) receptor expressed in CHO cells is activated by basic FGF and Kaposi FGF.

Mansukhani A, Moscatelli D, Talarico D, Levytska V, Basilico C.

Proc Natl Acad Sci U S A. 1990 Jun;87(11):4378-82.

45.

Expression of the K-fgf protooncogene is repressed during differentiation of F9 cells.

Velcich A, Delli-Bovi P, Mansukhani A, Ziff EB, Basilico C.

Oncogene Res. 1989;5(1):31-7.

PMID:
2780052
46.

Expression and activation of the K-fgf oncogene.

Basilico C, Newman KM, Curatola AM, Talarico D, Mansukhani A, Velcich A, Delli-Bovi P.

Ann N Y Acad Sci. 1989;567:95-103. Review. No abstract available.

PMID:
2679328
47.

DNA-binding properties of the Drosophila melanogaster zeste gene product.

Mansukhani A, Crickmore A, Sherwood PW, Goldberg ML.

Mol Cell Biol. 1988 Feb;8(2):615-23.

48.

Nucleotide sequence and structural analysis of the zeste locus of Drosophila melanogaster.

Mansukhani A, Gunaratne PH, Sherwood PW, Sneath BJ, Goldberg ML.

Mol Gen Genet. 1988 Jan;211(1):121-8.

PMID:
3125410
49.

Molecular cloning, germ-line transformation, and transcriptional analysis of the zeste locus of Drosophila melanogaster.

Gunaratne PH, Mansukhani A, Lipari SE, Liou HC, Martindale DW, Goldberg ML.

Proc Natl Acad Sci U S A. 1986 Feb;83(3):701-5.

50.

Cell culture mutants as aminoacyl-tRNA synthetase complex probes.

Hampel A, Mansukhani A, Condon T.

Fed Proc. 1984 Dec;43(15):2991-3.

PMID:
6500073

Supplemental Content

Loading ...
Support Center